BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32739322)

  • 1. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model.
    Yamamoto J; Miyake K; Han Q; Tan Y; Inubushi S; Sugisawa N; Higuchi T; Tashiro Y; Nishino H; Homma Y; Matsuyama R; Chawla SP; Bouvet M; Singh SR; Endo I; Hoffman RM
    Cancer Lett; 2020 Nov; 492():174-184. PubMed ID: 32739322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake M; Higuchi T; Oshiro H; Zhang Z; Razmjooei S; Wangsiricharoen S; Bouvet M; Singh SR; Unno M; Hoffman RM
    Cancer Lett; 2018 Sep; 432():251-259. PubMed ID: 29928962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
    Strekalova E; Malin D; Good DM; Cryns VL
    Clin Cancer Res; 2015 Jun; 21(12):2780-91. PubMed ID: 25724522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
    Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM
    Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.
    Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake K; Miyake M; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Eckardt MA; Unno M; Eilber FC; Hoffman RM
    Cell Cycle; 2018; 17(3):356-361. PubMed ID: 29187018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model.
    Sugisawa N; Yamamoto J; Han Q; Tan Y; Tashiro Y; Nishino H; Inubushi S; Hamada K; Kawaguchi K; Unno M; Bouvet M; Hoffman RM
    Pancreas; 2021 Jan; 50(1):93-98. PubMed ID: 33370029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.
    Higuchi T; Kawaguchi K; Miyake K; Han Q; Tan Y; Oshiro H; Sugisawa N; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Singh AS; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
    Anticancer Res; 2018 Oct; 38(10):5639-5644. PubMed ID: 30275182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase.
    Han Q; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1921-1926. PubMed ID: 33813397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Afterword: Oral Methioninase-Answer to Cancer and Fountain of Youth?
    Hoffman RM; Han Q; Kawaguchi K; Li S; Tan Y
    Methods Mol Biol; 2019; 1866():311-322. PubMed ID: 30725426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model.
    Higuchi T; Han Q; Miyake K; Oshiro H; Sugisawa N; Tan Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2020 Feb; 523(1):135-139. PubMed ID: 31839218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Murakami T; Li S; Han Q; Tan Y; Kiyuna T; Igarashi K; Kawaguchi K; Hwang HK; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Hiroshima Y; Lwin TM; DeLong JC; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Oncotarget; 2017 May; 8(22):35630-35638. PubMed ID: 28404944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review.
    Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Murakami T; Unno M; Hoffman RM
    Cells; 2019 May; 8(5):. PubMed ID: 31052611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral-recombinant Methioninase Converts an Osteosarcoma from Methotrexate-resistant to -sensitive in a Patient-derived Orthotopic-xenograft (PDOX) Mouse Model.
    Aoki Y; Tome Y; Han Q; Yamamoto J; Hamada K; Masaki N; Kubota Y; Bouvet M; Nishida K; Hoffman RM
    Anticancer Res; 2022 Feb; 42(2):731-737. PubMed ID: 35093871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
    Kawaguchi K; Higuchi T; Li S; Han Q; Tan Y; Igarashi K; Zhao M; Miyake K; Kiyuna T; Miyake M; Ohshiro H; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Singh SR; Eilber FC; Unno M; Hoffman RM
    Biochem Biophys Res Commun; 2018 Sep; 503(4):3086-3092. PubMed ID: 30166061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage IV Pancreatic Cancer Patient Treated With FOLFIRINOX Combined With Oral Methioninase: A Highly-Rare Case With Long-term Stable Disease.
    Kubota Y; Han Q; Hozumi C; Masaki N; Yamamoto J; Aoki Y; Tsunoda T; Hoffman RM
    Anticancer Res; 2022 May; 42(5):2567-2572. PubMed ID: 35489727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
    Sato M; Han Q; Mizuta K; Mori R; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
    In Vivo; 2024; 38(3):1459-1464. PubMed ID: 38688589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model.
    Park JH; Zhao M; Han Q; Sun Y; Higuchi T; Sugisawa N; Yamamoto J; Singh SR; Clary B; Bouvet M; Hoffman RM
    Biochem Biophys Res Commun; 2019 Oct; 518(2):306-310. PubMed ID: 31421825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model.
    Sugisawa N; Hamada K; Han Q; Yamamoto J; Sun YU; Nishino H; Kawaguchi K; Bouvet M; Unno M; Hoffman RM
    Anticancer Res; 2020 Sep; 40(9):4869-4874. PubMed ID: 32878774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.